Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

AustriaBack to Austria

Clinical trials in Vienna – page 45

841 clinical trials in Vienna, Austria across 10 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Vienna at a glance
841
clinical trials
  • Research sites10
Type of trial
Recruitment status
Quick filters

841 trials in Vienna

Open in trial search

Oesophageal squamous cell carcinoma

Not recruiting

Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Marginal zone lymphoma

Not recruiting

Study of Acalabrutinib and Tafasitamab for Patients with Previously Treated Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Obliterative bronchiolitis

Not recruiting

Study on Long-Term Safety and Effectiveness of Liposomal Ciclosporin A for Patients with Bronchiolitis Obliterans Syndrome After Lung Transplantation

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin A
  • Sponsor:Zambon S.p.A.

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Acute lymphocytic leukaemia+6

Not recruiting

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Pulmonary arterial hypertension

Not recruiting

Study Comparing the Effectiveness and Safety of Macitentan 75 mg and 10 mg for Patients with Pulmonary Arterial Hypertension

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Migraine

Not recruiting

Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Migraine

Not recruiting

Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Vienna

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including pancreatic ductal adenocarcinoma, gastric cancer, and non-small cell lung cancer. Studies evaluating new therapeutic approaches for breast cancer and multiple myeloma are also underway.

  • Advanced Cancer Therapies
  • Targeted Treatment Approaches
  • Immunotherapy Studies

Research includes evaluation of novel drug combinations and immunotherapy approaches for improved patient outcomes.

02 Neuropsychiatric Studies

Investigations into major depression and its treatment mechanisms, including studies on dopamine synthesis and antidepressant effectiveness. Research examines innovative therapeutic approaches using ketamine and other compounds.

  • Depression Treatment
  • Neuroimaging Research
  • Therapeutic Mechanisms

Focus on understanding brain activation patterns and treatment responses in psychiatric conditions.

03 Autoimmune and Inflammatory Conditions

Research on plaque psoriasis, rheumatic diseases, and Sjögren's syndrome. Studies evaluate new biological therapies and treatment approaches for chronic inflammatory conditions.

  • Novel Therapeutic Agents
  • Disease Modification
  • Long-term Treatment Outcomes

Emphasis on developing targeted therapies for improved disease management and patient quality of life.

Back to AustriaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.